A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial

M Cutolo, GE Myerson, RM Fleischmann… - The Journal of …, 2016 - jrheum.org
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …
被引用次数：233 相关文章

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

M Cutolo, GE Myerson, RM Fleischmann… - The Journal of …, 2016 - jrheum.org
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

M Cutolo, GE Myerson… - The Journal of …, 2016 - pubmed.ncbi.nlm.nih.gov
Objective Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

M Cutolo, GE Myerson, RM Fleischmann… - The Journal of …, 2016 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> Objective.</jats: title>< jats: p> Apremilast, an oral
phosphodiesterase 4 inhibitor, downregulates intracellular inflammatory mediator synthesis …

[引用][C] A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: Results of the PALACE 2 trial

M Cutolo, GE Myerson, RM Fleischmann… - Journal of …, 2016 - portalciencia.ull.es
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …
[PDF] academia.edu

[PDF][PDF] A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

M Cutolo, GE Myerson, RM Fleischmann… - The Journal of …, 2016 - academia.edu
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …
[PDF] psu.edu

[PDF][PDF] A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial

M Cutolo, GE Myerson, RM Fleischmann… - The Journal of …, 2016 - Citeseer
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial

M Cutolo, GE Myerson, RM Fleischmann… - JOURNAL OF …, 2016 - biblio.ugent.be
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

A Phase III, Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis: Results of the PALACE 2 Trial.

M Cutolo, GE Myerson, RM Fleischmann… - The Journal of …, 2016 - europepmc.org
Objective Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …

[引用][C] A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: Results of the PALACE 2 trial

M Cutolo, GE Myerson, RM Fleischmann… - Journal of …, 2016 - portalciencia.ull.es
Objective. Apremilast, an oral phosphodiesterase 4 inhibitor, downregulates intracellular
inflammatory mediator synthesis by elevating cyclic adenosine monophosphate levels. The …